Ixazomib/Enleri capsules: a new option for patients with multiple myeloma

Ixazomib capsules, as an oral proteasome inhibitor, have become a new option for the treatment of multiple myeloma (MM), especially for those patients who have poor response to traditional treatments or who are difficult to tolerate injectable drugs. As a new type of therapeutic drug, ixazomib has shown unique advantages in the treatment of multiple myeloma and also provides a treatment experience different from traditional treatment options.

Ixazomib inhibits the function of intracellular proteasomes and prevents the degradation of abnormal proteins in cancer cells, thereby leading to the death of tumor cells. In the treatment of multiple myeloma, proteasome inhibitors are one of the most important therapeutic drugs. They effectively control the disease by interfering with the survival mechanism of tumor cells. The mechanism of action of ixazomib is similar to that of the classic proteasome inhibitor Bortezomib (Bortezomib), but the difference is that ixazomib has the advantage of oral administration, which eliminates the need for patients to go to the hospital for injections every week or every two weeks, greatly improving the patient's quality of life and treatment compliance.

According to multiple clinical studies, ixazomib, when used in combination with Lenalidomide and Dexamethasone, can effectively improve the overall survival and progression-free survival of patients, especially in patients with relapsed or refractory multiple myeloma. In the study, patients who received the ixazomib combination showed longer progression-free survival and lower rates of disease recurrence than those who received placebo.

As an oral drug, ixazomib provides patients with a more convenient treatment option, especially for those who are elderly, have limited mobility, or require long-term treatment. The oral administration form is undoubtedly a more comfortable choice. In addition, ixazomib has relatively mild side effects, especially the incidence of gastrointestinal reactions and peripheral neuropathy, which are reduced compared with other proteasome inhibitors, which further enhances its acceptability as a treatment option.

Reference materials:https://www.ninlaro.com/